Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 4 2Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 8Sarcoma 3Gastrointestinal 3Head & Neck 2Gynecologic 2CNS 2Tumor-Agnostic 1Breast 1

Conditions

Nasopharyngeal Carcinoma 2

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 11tremelimumab 9Gemcitabine 9Ipilimumab 8fludarabine 7avelumab 7Erlotinib Hydrochloride 7toripalimab 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × anlotinib × Head & Neck × Clear all
NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Sun Yat-sen University

Phase 1/2 Not yet recruiting
52 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT03639467 2018-09-18

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

ChineseAMS

Phase 1/2 Unknown
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡